Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKTURNA vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension (to lower blood pressure, alone or in combination with other antihypertensives)
Hypertension
150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is approximately 24 hours (range 20–40 hours), supporting once-daily dosing.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Primarily hepatic via CYP3A4; minor metabolism via other pathways. Excreted in feces (78%) and urine (22%).
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal (88% as unchanged drug and metabolites, 33% as unchanged aliskiren); biliary/fecal elimination accounts for approximately 12%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Approximately 50% bound to plasma proteins (primarily albumin).
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Volume of distribution is approximately 1.7 L/kg, indicating extensive distribution into tissues.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral bioavailability is approximately 2.5% (low due to limited absorption and high first-pass metabolism); absorption is reduced by high-fat meal (by up to 50%).
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated in GFR <30 m L/min/1.73 m². For GFR ≥30 m L/min/1.73 m², no dose adjustment required.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not studied in severe hepatic impairment (Child-Pugh Class C).
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not approved for use in pediatric patients under 18 years of age due to lack of safety and efficacy data.
Not established; avoid use in children.
No dose adjustment required in elderly patients; initiate therapy at 150 mg once daily and monitor renal function and blood pressure closely due to increased risk of hypotension and renal impairment.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
Fetal toxicity (avoid in pregnant women; discontinue if pregnancy detected),Hypotension in volume-depleted patients,Renal impairment (monitor renal function; risk of acute renal failure in patients with bilateral renal artery stenosis),Hyperkalemia (especially in patients with renal impairment, diabetes, or on potassium-sparing diuretics),Angioedema (discontinue immediately and manage appropriately)
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Pregnancy,History of angioedema with previous renin-angiotensin system inhibitors,Concomitant use with aliskiren in patients with diabetes (age- and renal-specific restrictions)
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
High-fat meals reduce aliskiren absorption; avoid consistent consumption with high-fat foods. Grapefruit juice may decrease aliskiren levels; avoid concurrent intake. No other significant food interactions.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal injury and death when used during the second and third trimesters. Risks include oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. First trimester exposure may also carry increased risk but is less well-defined.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
No data on presence in human milk; manufacturer advises against breastfeeding due to potential adverse effects in nursing infants, including hypotension and renal impairment.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No specific dose adjustments recommended; avoid use in pregnancy, especially during second and third trimesters, due to risk of fetal harm. If pregnancy occurs, discontinue promptly.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
TEKTURNA (aliskiren) is a direct renin inhibitor used for hypertension. Monitor renal function and potassium levels due to risk of hyperkalemia and renal impairment, especially in patients with diabetes, renal artery stenosis, or concomitant ACE/ARB use. Avoid use during pregnancy (category D). Contraindicated with cyclosporine and itraconazole due to increased aliskiren exposure.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take TEKTURNA once daily with or without food, but consistently either with a meal or without.,Avoid high-fat meals as they can reduce absorption.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not use salt substitutes containing potassium without consulting your doctor.,Report symptoms like muscle cramps, irregular heartbeat, or weakness (signs of hyperkalemia).,Stay hydrated and avoid dehydration (vomiting, diarrhea, excessive sweating) as it may increase side effects.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKTURNA vs ALDORIL 25, answered by our medical review team.
TEKTURNA is a Antihypertensive that works by Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKTURNA and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKTURNA is: 150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKTURNA and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKTURNA is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal injury and death when used during the second and third trimesters. Risks include oligohydramnios, fetal . ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.